FDA head explains decision to drop ‘black box’ warnings from menopause hormone treatment

The FDA announced it would begin asking drug companies to remove so-called “black box” warnings for hormones prescribed to treat symptoms of menopause. The FDA says the warning has dissuaded generations of women from taking advantage of the medication that could help them. Ali Rogin discussed more with FDA Commissioner Dr. Marty Makary. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy